Understanding how amyloid peptides clump together in Alzheimer's disease
Official title: Pathways and interactions accounting for the oligomerization of amyloid peptides
Funded at New Jersey Institute of Technology · NIH-10580438 · Data updated 2026-11-12
This study is looking at how certain proteins in the brain clump together in Alzheimer's disease and how these clumps can harm brain cells, with the hope of finding new ways to stop or slow down this process to help people with Alzheimer's.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New Jersey Institute of Technology NIH-funded |
| Lab location | 1 site (Newark, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $474,325 |
| NIH project number | 1R15GM148982-01 |
| Project ID | NIH-10580438 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of developing Alzheimer's disease or those in the early stages of the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have amyloid-related conditions may not benefit from this research.
What this research studies
This research investigates the process by which amyloid peptides aggregate into harmful structures in Alzheimer's disease. It focuses on the interactions between these aggregates and cell membranes, which can lead to cell damage. By using advanced molecular simulations and laboratory experiments, the study aims to uncover the mechanisms behind the formation of these aggregates, particularly how they form on existing fibrils. The ultimate goal is to develop new treatments that can prevent or reduce the aggregation of these peptides, potentially slowing the progression of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new preventive treatments for Alzheimer's disease, improving the quality of life for patients.
How similar studies have gone: Previous research has shown promise in understanding amyloid aggregation, but this approach focusing on secondary nucleation is relatively novel.
Where this research is happening
-
New Jersey Institute of Technology
Newark, United States Active
Researchers
- Principal investigator: Dias, Cristiano Luis — New Jersey Institute of Technology
- Study coordinator: Dias, Cristiano Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.